Blockade of IGF-IR exerts anticancer effects in hepatocellular carcinoma

Molecular Medicine Reports

Volumn 4, Issue 4, 2011, Pages 719-722

  Yao, Wei Feng ^a   Liu, Jun Wei ^b   Sheng, Guo Liang ^b   Huang, Dong Sheng ^a,b  

^a Hangzhou Xiasha Hospital   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Hepatocellular carcinoma; Insulin like growth factor receptor inhibitor

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; CYTOCHROME C; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROCASPASE 3; SOMATOMEDIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL STRAIN HEPG2; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL LINE, TUMOR; CELL MOVEMENT; CYTOCHROMES C; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIVER NEOPLASMS; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; TYRPHOSTINS;

EID: 79957634790     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.486     Document Type: Article

References (24)

1. Michalopoulos GK and DeFrances MC: Liver regeneration. Science 276: 60-66, 1997.
2. Fausto N, Laird AD, and Webber EM: Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. Faseb J 9: 1527-1536, 1995.
3. Pietrzkowski Z, Mulholland G, Gomella L, et al: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53: 1102-1106, 1993. (Pubitemid 23087914)
4. Scrimgeour AG, Blakesley VA, Stannard BS, and LeRoith D: Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis. Endocrinology 138: 2552-2558, 1997. (Pubitemid 27215262)
5. Sell C, Baserga R and Rubin R: Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 55: 303-306, 1995.
6. Scotlandi K, Benini S, Nanni P, et al: Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 58: 4127-4131, 1998. (Pubitemid 28440569)
7. Shapiro DN, Jones BG, Shapiro LH, et al: Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 94: 1235-1242, 1994. (Pubitemid 24286468)
8. Salisbury AJ and Macaulay VM: Development of molecular agents for IGF receptor targeting. Horm Metab Res 35: 843-849, 2003. (Pubitemid 38058192)
9. Nardone G, Romano M, Calabro A, et al: Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatology 23: 1304-1312, 1996. (Pubitemid 26181208)
10. Hopfner M, Sutter AP, Huether A, et al: Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J Gastroenterol 12: 5635-5643, 2006. (Pubitemid 44594037)
11. Hopfner M, Baradari V, Huether A, et al: The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 13: 135-149, 2006.
12. Camiran A, Zakikhani M, Young F, et al: Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 7: R570-R579, 2005.
13. Deutsch E, Maggiorella L, Wen B, et al: Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. Br J Cancer 91: 1735-1741, 2004. (Pubitemid 39546148)
14. Liu B, Staren E, Iwamura T, et al: Effects of taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2. World J Gastroenterol 7: 143-148, 2001. (Pubitemid 32170917)
15. Wolf WC, Evans DM, Chao L, et al: A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol 159: 1797-1805, 2001. (Pubitemid 33062522)
16. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
17. Verspohl EJ, Maddux BA and Goldfine ID: Insulin and insulin-like growth factor I regulate the same biological functions in HEP-G2 cells via their own specific receptors. J Clin Endocrinol Metab 67: 169-174, 1988.
18. Humbel RE: Insulin-like growth factors I and II. Eur J Biochem 190: 445-462, 1990.
19. Macaulay VM: Insulin-like growth factors and cancer. Br J Cancer 65: 311-320, 1992.
20. Baserga R: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55: 249-252, 1995.
21. Thomas D, Guthridge M, Woodcock J, et al: 14-3-3 protein signaling in development and growth factor responses. Curr Top Dev Biol 67: 285-303, 2005. (Pubitemid 43588856)
22. Hopfner M, Huether A, Sutter AP, et al: Blockade of IGF-I receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 71: 1435-1448, 2006.
23. Du C, Fang M, Li Y, et al: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33-42, 2000.
24. Boldin MP, Goncharov TM, Goltsev YV, et al: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85: 803-815, 1996.